와파린 나트륨(CAS 129-06-6) 시장 규모는 2024년에 1,976억 9,000만 달러로 평가되었고, 2026-2032년 연평균 4.60% 성장하여 2032년에는 2,833억 3,000만 달러에 달할 것으로 예측됩니다.
혈액 응고 방지를 위한 와파린 나트륨에 대한 선호도가 높아지면서 헬스케어 분야에서 이 제품에 대한 수요가 증가하여 세계 시장 성장을 가속하고 있습니다. 세계의 와파린 나트륨(CAS 129-06-6) 시장 보고서는 시장의 전반적인 평가를 담고 있습니다. 주요 부문, 동향, 시장 성장 촉진요인, 억제요인, 경쟁 구도, 시장에서 중요한 역할을 하는 요인 등을 종합적으로 분석합니다.
와파린 나트륨(CAS 129-06-6) 시장은 연평균 4.60%의 연평균 복합 성장률(CAGR)로 성장하여 2032년 말까지 2,833억 달러에 달할 것으로 예측됩니다.
세계의 와파린 나트륨(CAS 129-06-6) 시장 정의
와파린 나트륨은 와파린의 나트륨 염으로 항응고 작용을 하며, CAS 129-06-6은 Chemical Abstracts Service에서 부여한 와파린 나트륨의 고유한 수치 식별자입니다. 심부정맥혈전증, 폐색전증과 같은 혈전 치료 및 심방세동, 심장판막증, 인공심장판막을 가진 사람의 뇌졸중 예방에 일반적으로 사용됩니다. 와파린 나트륨은 1mg 정제, 2.5mg 정제, 5mg 정제 등 세 가지 유형로 나뉩니다.
일반적으로 경구 복용하지만 정맥 주사로도 사용할 수 있습니다. 와파린 나트륨은 비타민 K와 비타민 K 에폭시드 환원효소를 억제하여 비타민 K 에폭시드에서 그 환원형인 비타민 KH2로의 주기적 상호 전환을 억제합니다. 비타민KH2는 비타민K 의존성 단백질의 N말단 영역에 존재하는 글루탐산 카르복실화 보효소입니다. 가장 흔한 부작용은 출혈이며, 덜 흔한 부작용으로는 조직 손상 부위 및 발가락 보라색 증후군이 있습니다.
세계 와파린 나트륨(CAS 129-06-6) 시장 개요
이처럼 혈액 응고 예방을 위해 와파린 나트륨에 대한 선호도가 높아짐에 따라 헬스케어 분야에서 이 제품에 대한 수요가 증가하여 세계 시장 성장을 가속하고 있습니다. 그러나 적색 또는 갈색 소변, 흑색 또는 혈변, 심한 두통 또는 복통, 관절통, 구토, 구토, 토혈 등 와파린 나트륨의 몇 가지 부작용이 세계 시장 성장을 저해하고 있습니다. 또한, 와파린 나트륨의 과다 복용은 심한 하혈과 평소보다 더 심한 월경 출혈로 이어질 수 있으며, 이는 시장 성장을 제한할 것으로 예측됩니다.
Warfarin Sodium (CAS 129-06-6) Market size was valued at USD 197.69 Billion in 2024 and is projected to reach USD 283.3 Billion by 2032, growing at a CAGR of 4.60% from 2026 to 2032.
The increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. The Global Warfarin Sodium (CAS 129-06-6) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Warfarin Sodium (CAS 129-06-6) Market is estimated to grow at a CAGR of 4.60% & reach US$ 283.3 Bn by the end of 2032
Global Warfarin Sodium (CAS 129-06-6) Market Definition
Warfarin Sodium is the sodium salt form of warfarin, with anticoagulant activity. CAS 129-06-6 is a unique numerical identifier of warfarin sodium assigned by the Chemical Abstracts Service. It is commonly used to treat blood clots such as deep vein thrombosis and pulmonary embolism, and to prevent stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Warfarin Sodium is categorized into three types: 1 mg/Tablet, 2.5 mg/Tablet, and 5 mg/Tablet.
It is generally taken by mouth, but can also be used by injection into a vein. Warfarin sodium inhibits vitamin K and vitamin K epoxide reductases, thereby obstructing the cyclic interconversion of vitamin K epoxide to its diminished form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate resting on the N-terminal regions of vitamin K-dependent proteins. The most common side effect is bleeding and less common side effects include areas of tissue damage and purple toes syndrome.
Global Warfarin Sodium (CAS 129-06-6) Market Overview
Thus, the increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. However, the several side effects of warfarin sodium such as red or brown urine, black or bloody stool, severe headache or stomach pain, joint pain, vomiting, and coughing up blood are hampering the global market growth. Overdose of warfarin sodium also leads to severe blooding or heavier than normal menstrual bleeding, which is also expected to restrict the market growth.
The Global Warfarin Sodium (CAS 129-06-6) Market Is Segmented On The Basis Of Type, Application, And Geography.
Based on Type, the market is segmented into 1mg/Tablet, 2.5mg/Tablet, and 5mg/Tablet. Warfarin, an anticoagulant works by preventing the formation of harmful blood clots. Although it does not dissolve the existing blood clots, it prevents them from growing larger and causing blockages in the blood vessels. It also has a common side effect of Bleeding. Hence it is always advised to consume Warfarin in small amounts. Hence 1mg/Tablets are consumed more and these factors are expected to boost demand for 1mg/Tablets and further propel market growth.
Based on Application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies usually stock a larger variety of medications, including more specialized and investigational medications, than would be feasible in the community setting. Pharmacists in hotels are more trained and equipped. Warfarin can interact with several medicines hence expert advice is always needed. These factors are expected to boost demand and further propel market growth.
The "Global Warfarin Sodium (CAS 129-06-6) Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.